Today's Rundown Featured Story | | | Tuesday, January 8, 2019 It feels like there’s a little more than just precipitation in the air at the J.P. Morgan Healthcare Conference this year: a dash of optimism and cash. |
|
|
Top Stories Tuesday, January 8, 2019 The FDA is creating an office of drug development science to cut the cost of bringing new medicines to patients, BioCentury reports. Staff at the office will create tools that sponsors and the FDA can use to streamline the development and regulatory assessment of drugs. Tuesday, January 8, 2019 Allogeneic CAR-T therapy, which uses donor T cells, has the potential to clear the hurdles that come with autologous CAR-T, which uses a patient’s own T cells. Those challenges include the cost, complexity and time-consuming nature of autologous treatments, as well as distribution and market access. Monday, January 7, 2019 Biopharmaceutical science has the capability to drive change in our society and write a new storyline for public health. However, science alone will not achieve this change. So what can? Tuesday, January 8, 2019 Apollomics has raised $100 million to fund a multifront oncology clinical trial program while moving its headquarters from China to California. The series B round sets Apollomics up to advance its c-Met inhibitor and pipeline of other clinical-phase assets. Tuesday, January 8, 2019 A collaboration between California’s Unity Biotech and China’s Ascentage Pharma has yielded another development candidate—a drug to treat age-related diseases of the eye. Monday, January 7, 2019 Germany’s Boehringer Ingelheim will work with Vanderbilt University to develop novel small molecules that modulate brain circuits by targeting G-protein coupled receptors (GPCRs), which could provide relief for a variety of symptoms, including memory loss, social withdrawal and the lack of motivation, they believe. Tuesday, January 8, 2019 There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to. “We’re very active,” CEO Ken Frazier said during a Monday afternoon fireside chat at the J.P. Morgan Healthcare Conference. What's the holdup, then? Resources Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
